GlassScriptPhysician profile
Grayson P Jordan
NPI 1578913976
$8,062.88
in general payments reported to CMS, 2019-2025
45 companies · $1,573 in 2025
The $1,573 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $982 · 2021: $1,251 · 2022: $1,170 · 2023: $1,430 · 2024: $1,391 · 2025: $1,573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,394.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,439.37 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $793.34 | 2019-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $791.96 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $632.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $624.30 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $602.41 | 2020-2025 | |
| Amgen INC. | $373.74 | 2019-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $338.94 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.94 | 2020-2025 | Synjardy, Tradjenta, Jardiance |
| Otsuka America Pharmaceutical, INC. | $254.87 | 2022-2025 | Rexulti |
| Esperion Therapeutics, INC. | $239.47 | 2020-2025 | Nexletol |
| Glaxosmithkline, LLC. | $160.50 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $147.87 | 2021-2022 | |
| Abbott Laboratories | $140.53 | 2022-2025 | |
| Exact Sciences Corporation | $127.16 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grayson Jordan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.